This story has been updated with comments from a company earnings call.

NEW YORK (Genomeweb News) – Vermillion reported today that its second quarter revenues were $535,000, up 65 percent from $324,000 in Q2 2014 but falling short of the average Wall Street estimate of $1.2 million.

The company posted product revenue of $535,000, up 153 percent from $211,000 in Q2 2014. It had no license revenue, compared to $113,000 in the year-ago period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.